4.7 Review

A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression

Journal

JOURNAL OF CLINICAL MEDICINE
Volume 9, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/jcm9051369

Keywords

NAFLD; gut microbiome; microbial metabolic pathway; microbiome-based signature; fecal microbiota transplantation

Funding

  1. Spanish Ministry of Science and Technology [BFU2017-86378-P]
  2. Fondo Investigaciones Sanitarias [PI18/01304]
  3. Gilead Fellowship programme 2018

Ask authors/readers for more resources

Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease in which environmental and genetic factors are involved. Although the molecular mechanisms involved in NAFLD onset and progression are not completely understood, the gut microbiome (GM) is thought to play a key role in the process, influencing multiple physiological functions. GM alterations in diversity and composition directly impact disease states with an inflammatory course, such as non-alcoholic steatohepatitis (NASH). However, how the GM influences liver disease susceptibility is largely unknown. Similarly, the impact of strategies targeting the GM for the treatment of NASH remains to be evaluated. This review provides a broad insight into the role of gut microbiota in NASH pathogenesis, as a diagnostic tool, and as a therapeutic target in this liver disease. We highlight the idea that the balance in metabolic fermentations can be key in maintaining liver homeostasis. We propose that an overabundance of alcohol-fermentation pathways in the GM may outcompete healthier, acid-producing members of the microbiota. In this way, GM ecology may precipitate a self-sustaining vicious cycle, boosting liver disease progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available